News | Stents Drug Eluting | June 03, 2016

ORIENT Trial Results on Orsiro Hybrid Drug-Eluting Stent Presented at EuroPCR 2016

Data establish Orsiro's non-inferiority to Resolute Integrity Stent; STEMI subgroup from BIOSCIENCE trial has 50 Percent lower target lesion failure rate versus Xience

Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent

June 3, 2016 — Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute Integrity DES were presented during a Hotline Session at EuroPCR 2016. The multicenter, randomized, controlled all-comers ORIENT trial enrolled 372 patients who received either Orsiro or Resolute Integrity in treatment of a wide variety of coronary heart disease.

“Orsiro’s refined design, including a biodegradable polymer and ultrathin struts, improve patient safety and angiographic outcomes,” commented ORIENT trial principal investigator Tae-Jin Youn, M.D., Seoul National University Bundang Hospital, South Korea. “In this trial, Orsiro conclusively demonstrated non-inferiority to the competitor DES in terms of in-stent late lumen loss.”

The ORIENT trial’s primary endpoint was in-stent late lumen loss (LLL) at nine months, an angiographic endpoint. Orsiro demonstrated significant non-inferiority for the primary end point — at nine months the trial’s Orsiro arm had an average LLL of 0.10 ± 0.35, while patients in the Resolute Integrity arm had an LLL of 0.16 ± 0.39 (P for non-inferiority=<0.001). The trial furthermore highlighted Orsiro’s excellent safety profile, with no stent thrombosis observed.

At EuroPCR 2016, positive 24 months results for ST-segment elevation myocardial infarction (STEMI) patients were also presented as part of the official program and during a scientific symposium on Orsiro. STEMI is a potentially fatal type of heart attack caused by a prolonged obstruction of blood supply in the heart. Every year nearly 250,000 people experience STEMI heart attacks. A subanalysis of 407 STEMI patients was included in the multicenter, randomized, controlled non-inferiority BIOSCIENCE trial. Results from the trial have been published in The Lancet and EuroIntervention; these had already revealed that Orsiro might be associated with better clinical outcomes than Xience Prime/Xpedition for this indication.

At two years, BIOSCIENCE’s primary endpoint of target lesion failure (TLF) occurred in 5.4 percent of STEMI patients treated with Orsiro compared with 10.8 percent of those treated with Xience Prime/Xpedition. BIOSCIENCE is the largest investigator-initiated study to date evaluating the safety and efficacy of Orsiro, a bioabsorbable polymer DES, in comparison to the durable polymer Xience Prime/Xpedition DES.

The Orsiro Hybrid Drug-Eluting Stent (DES), launched in 2011, combines passive and active components. proBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and the surrounding tissue. BIOlute active coating contains a highly biocompatible polymer that delivers a limus drug via a bioabsorbable matrix. This hybrid coating is layered on top of the high performance PRO-Kinetic Energy stent platform, renowned for its advanced ultrathin-strut stent design and outstanding deliverability.

For more information: www.biotronik.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init